One-time gene therapy may lower up to 62 pc ‘bad’ cholesterol, clinical trial results show
New Delhi, May 27 (PTI) A one-time gene therapy for treating hypercholesterolaemia could lower up to 62 per cent ‘bad’ cholesterol in the blood, with reductions sustaining over time, according to results of Phase 1b clinical trial published in The New England Journal of Medicine. Developed by the US-based pharmaceutical and biotechnology giant Eli Lilly and Company, VERVE-102 is an experimental gene therapy that works by durably turning off the ‘PCSK9’ gene in the liver and lower blood levels of low-density lipoprotein cholesterol (LDL-C) following a single infusion, it said in a statement. The interim analysis of the ‘Heart-2’ trial